IP Library Patent Application 14977137
Patent Application
App. No. 14/977,137

LIQUID INSULIN FORMULATIONS AND METHODS RELATING THERETO

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/977,137
Abstract

Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.

Claims (21)

1 . An insulin formulation, comprising:

insulin at a minimal concentration of 1-13 mM;

a salt at a concentration of 50-150 mM;

a pH buffering agent at a concentration of 3-24 mM;

zinc at a ratio of 1.9-2.7 zinc ions per insulin hexamer; and

a pH in the range of 7.2 to 8.0,

wherein the formulation does not contain preservatives or stabilizers.

2 . The formulation of claim 1 , wherein the insulin is human insulin.

3 . The formulation of claim 1 , wherein the formulation comprises at least 30 mg/mL insulin.

4 . The formulation of claim 1 , wherein the formulation comprises 10-30 mg/mL insulin.

5 . The formulation of claim 1 , wherein the insulin concentration is about 30 mg/mL and the pH is about 7.55.

6 . The formulation of claim 1 , wherein the salt is a chloride salt.

7 . The formulation of claim 1 , wherein the salt is NaCl.

8 . The formulation of claim 1 , wherein the pH buffering agent comprises citrate.

9 . The formulation of claim 1 , wherein the tonicity (ionic strength) of the formulation is 100-300 mOsm.

10 . The formulation of claim 1 , wherein the formulation is administrable by inhalation or injection.

11 . The formulation of claim 1 , wherein the formulation is administrable by an inhalation device.

12 . The formulation of claim 1 , wherein the formulation is aerosolizable.

13 . The formulation of claim 1 , wherein the formulation does not contain surfactants.

14 . A unit dose of the pharmaceutically acceptable formulation of claim 1 .

15 . A method of treating a subject with diabetes mellitus, comprising administering to a subject having diabetes mellitus a therapeutically effective amount of the formulation according to claim 1 , wherein the formulation is administered to the subject via inhalation or injection.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 3, 2016
From: HERCULES TECHNOLOGY III, LP
To: DANCE BIOPHARM HOLDINGS, INC.; DANCE BIOPHARM INC.
Reel/Frame 040215/0128 →
SECURITY INTEREST Recorded Nov 3, 2016
From: DANCE BIOPHARM HOLDINGS, INC.; DANCE BIOPHARM, INC.
To: GPB DEBT HOLDINGS II, LLC, AS AGENT FOR THE FOLLOWING:; DOMINION CAPITAL LLC
Reel/Frame 040215/0239 →
SECURITY INTEREST Recorded Aug 31, 2016
From: DANCE BIOPHARM, INC.; DANCE BIOPHARM HOLDINGS, INC.
To: HERCULES TECHNOLOGY III, L.P.
Reel/Frame 039603/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2016
From: BUECHE, BLAINE; KUO, MEI-CHANG; PATTON, JOHN S.; SANDER, MATTHEW
To: DANCE BIOPHARM, INC.
Reel/Frame 037762/0517 →